Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957847 | 1.00 | KRAS (0.49) | KRASSOS1 | |
| Hydrochloric Acid SCHEMBL30957877 | 0.99 | KRAS (0.49) | KRASSOS1 | |
| SCHEMBL28557210 | 0.92 | KRAS (0.42) | KRASSOS1 | |
| SCHEMBL20560390 | 0.92 | KRAS (0.48) | KRAS | |
| SCHEMBL28559212 | 0.91 | KRAS (0.42) | KRASSOS1 | |
| SCHEMBL24459922 | 0.91 | KRAS (0.47) | KRAS | |
| Hydrochloric Acid SCHEMBL31636208 | 0.91 | KRAS (0.47) | KRAS | |
| SCHEMBL28563035 | 0.90 | KRAS (0.42) | KRASSOS1 | |
| SCHEMBL29614874 | 0.89 | KRAS (0.40) | KRASSOS1 | |
| SCHEMBL28566364 | 0.88 | KRAS (0.42) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345701-B1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210300920-A1 | KRAS Mutant Protein Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2020239123-A1 | AROMATIC HETEROCYCLIC DERIVATIVE MODULATOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300920-A1 | KRAS Mutant Protein Inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 119/4885 |
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 119/4885 |
| US-11345701-B1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.